Biondvax Pharmaceuticals Ltd - ADR BVXV shares are trading lower by 58.60% to $3.64 during Friday's session after the company priced its 1.6 million unit offering at $5 per unit.
Biondvax Pharmaceuticals says the offering is expected to close on December 20, subject to the satisfaction of customary closing conditions.
Biondvax Pharmaceuticals expects to use the net proceeds from the offering, together with its existing cash and cash equivalents, for the advancement of its NanoAbs development program, as well as general corporate purposes.
According to data from Benzinga Pro, BVXV has a 52-week high of $34.90 and a 52-week low of $3.52.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.